Characteristics and Quality Appraisal of the Economic Evaluations Done in Ethiopia: A Systematic Review

Bereket Bahiru Tefera (), Desalegn Getnet Demsie, Adane Yehualaw, Chernet Tafere, Kebede Feyisa, Malede Berihun Yismaw, Belayneh Kefale and Zewdu Yilma
Additional contact information
Bereket Bahiru Tefera: Bahir Dar University College of Medicine and Health Sciences
Desalegn Getnet Demsie: Bahir Dar University College of Medicine and Health Sciences
Adane Yehualaw: Bahir Dar University College of Medicine and Health Sciences
Chernet Tafere: Bahir Dar University College of Medicine and Health Sciences
Kebede Feyisa: Bahir Dar University College of Medicine and Health Sciences
Malede Berihun Yismaw: Bahir Dar University College of Medicine and Health Sciences
Belayneh Kefale: Bahir Dar University College of Medicine and Health Sciences
Zewdu Yilma: Bahir Dar University College of Medicine and Health Sciences

PharmacoEconomics - Open, 2023, vol. 7, issue 6, No 2, 877-886

Abstract: Abstract Background Health economic evaluation identifies, measures, values, and compares alternative strategies to efficiently allocate scarce resources. The validity, methodological quality, and generalizability of economic evaluations must be assessed, as poorly designed studies can lead to incorrect conclusions. Therefore, this study aimed to evaluate the quality and characteristics of published economic evaluations done in Ethiopia, using the Quality of Health Economics Studies (QHES) and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) instruments. Methodology Various electronic databases were searched using different keywords. We included only original studies conducted in Ethiopia that evaluated the cost and consequences of at least two health interventions. Abstracts, treatment guidelines, reviews, expert opinions, and studies that included other countries were excluded. Two reviewers independently evaluated each study using the QHES and CHEERS instruments and any disagreements were then resolved by a third reviewer. Result The study included 21 studies published between 2002 and 2021. HIV was the most frequently evaluated medical condition, examined in four (19.06%) of the 21 studies. Seventeen of the studies (80.95%) compared healthcare services or programs, while the other four examined pharmaceutical products. Cost-utility analysis was the economic evaluation technique used in 14 studies (66.67%). Of the studies that disclosed their funding sources, foreign institutions were involved in funding 71.43% of them. Disability-adjusted life-year (DALY) was an outcome metric used in nine (42.86%) studies. The average QHES score of the studies was 82%. Fourteen studies had QHES scores of ≥75% and two had scores of

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-023-00433-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:7:y:2023:i:6:d:10.1007_s41669-023-00433-y

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-023-00433-y

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().